22.626 articles found

Pharmacological therapy in Parkinson's disease: focus on neuroprotection.

Kincses ZT, Vecsei L.

CNS Neurosci Ther · 2010-04-23

DOI: 10.1111/j.1755-5949.2010.00150.xPMID: 20438581

MPTP treatment increases expression of pre-pro-nociceptin/orphanin FQ mRNA in a subset of substantia nigra reticulata neurons.

Gouty S, Brown JM, Rosenberger J, Cox BM.

Neuroscience · 2010-04-22

DOI: 10.1016/j.neuroscience.2010.04.033PMID: 20417255

BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES

DUTTA ALOKE K.

· 2010-04-21

Post-MPTP treatment with granulocyte colony-stimulating factor improves nigrostriatal function in the mouse model of Parkinson's disease.

McCollum M, Ma Z, Cohen E, Leon R, Tao R, Wu JY, Maharaj D, Wei J.

Mol Neurobiol · 2010-04-21

DOI: 10.1007/s12035-010-8118-4PMID: 20405343

Selective Serotonin 2A/2C Receptor Inverse Agonists as Therapeutics for Neurodegenerative Diseases

WEINER DAVID M, DAVIS ROBERT E, BRANN MARK R, ANDERSSON CARL-MAGNUS A, ULDAM ALLAN K.

· 2010-04-13

Selective Serotonin 2A/2C Receptor Inverse Agonists as Therapeutics for Neurodegenerative Diseases

WEINER DAVID M, DAVIS ROBERT E, BRANN MARK R, ANDERSSON CARL-MAGNUS A, ULDAM ALLAN K.

· 2010-04-13

PROCESS FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, RHEUMATOID ARTHRITIS, TREMORS/PARKINSON'S DISEASE, MULTIPLE SCLEROSIS, NON-VIRAL BASED CANCERS, ALZHEIMERS'S DISEASE, MUSCULAR DYSTROPHY, ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, COMPLEX REGIONAL PAIN SYNDROME, DIABETES, NEUROPATHIC PAIN, SPIDER ARTHRITIS, WEST NILE VIRUS, FIBROMYALGIA, SHINGLES, GOUT, MIGRAINE HEADACHES, SENILE DEMENTIA, POST POLIO SYNDROME, CENTRAL VIRUS DEAFNESS, ASTHMA, CHRONIC PAIN OF UNKNOWN ORIGIN AND HEPATITIS C

NELSON GEORGE.

· 2010-04-13

Risk of Parkinson's disease after tamoxifen treatment.

Latourelle JC, Dybdahl M, Destefano AL, Myers RH, Lash TL.

BMC Neurol · 2010-04-12

DOI: 10.1186/1471-2377-10-23PMID: 20385012

Successful treatment of post-stroke apathy by the dopamine receptor agonist ropinirole.

Kohno N, Abe S, Toyoda G, Oguro H, Bokura H, Yamaguchi S.

J Clin Neurosci · 2010-04-08

DOI: 10.1016/j.jocn.2009.09.043PMID: 20378354

A translational approach to vocalization deficits and neural recovery after behavioral treatment in Parkinson disease.

Ciucci MR, Vinney L, Wahoske EJ, Connor NP.

J Commun Disord · 2010-04-08

DOI: 10.1016/j.jcomdis.2010.04.004PMID: 20434728

Daytime sleepiness in elderly Parkinson's disease patients and treatment with the psychostimulant modafinil: A preliminary study.

Lökk J.

Neuropsychiatr Dis Treat · 2010-04-07

DOI: 10.2147/ndt.s9138PMID: 20396641

Development and validation of a screening assay for the evaluation of putative neuroprotective agents in the treatment of Parkinson's disease.

Yong-Kee CJ, Salomonczyk D, Nash JE.

Neurotox Res · 2010-04-02

DOI: 10.1007/s12640-010-9174-2PMID: 20361292